StockWatch
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Quarterly ResultAug 6, 2026, 04:25 PM

Hyperfine Q2 Sales $3.9M, EPS $(0.09); Cash $43.4M

AI Summary

Hyperfine, Inc. reported increased sales and an improved net loss per share for the second quarter and first half of 2026. Q2 sales grew to $3.904 million, while net loss per share improved to $(0.09). The company significantly bolstered its cash position to $43.458 million, primarily through $13.641 million in new debt and $11.375 million from an at-the-market offering. Additionally, Hyperfine achieved key regulatory milestones, including CE Mark and UKCA Mark approvals for its next-generation Swoop® scanner and Optive AI™ software in March 2026.

Key Highlights

  • Q2 2026 total sales increased to $3.904 million from $2.696 million in Q2 2025.
  • Q2 2026 net loss per share improved to $(0.09) from $(0.12) in Q2 2025.
  • Cash and cash equivalents rose to $43.458 million as of June 30, 2026.
  • Long-term debt stood at $13.235 million as of June 30, 2026.
  • Received $13.641 million from debt issuance in the first six months of 2026.
  • Generated $11.375 million from at-the-market offering in the first six months of 2026.
  • Achieved CE Mark and UKCA Mark for next-gen Swoop® scanner and Optive AI™ software in March 2026.